48th week of 2008 patent applcation highlights part 46 |
Patent application number | Title | Published |
20080293579 | Crystal structure of polo-like kinase 3 (PLK3) and binding pockets thereof - The invention relates to molecules or molecular complexes, which comprise binding pockets of PLK3 or its structural homologues. The invention relates to crystallizable compositions and crystals comprising PLK3. The present invention also relates to a data storage medium encoded with the structural coordinates of molecules and molecular complexes which comprise the PLK3 or PLK3-like ATP-binding pockets. The present invention also relates to a computer comprising such data storage material. The computer may generate a three-dimensional structure or graphical three-dimensional representation of such molecules or molecular complexes. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen for, identify and design compounds, including inhibitory compounds that bind to PLK3 or homologues thereof. | 2008-11-27 |
20080293580 | Methods for Detecting and Measuring Specific Nucleic Acid Sequences - The invention provides novel oligonucleotides and methods of using the same for detection or measurement of specific nucleic acid molecules. The invention also features nucleic acid arrays comprising the oligonucleotides of the invention. An oligonucleotide of the invention comprises (1) a reporter-binding sequence capable of hybridizing to a fluorrophore-labeled reporter sequence and (2) a hairpin-forming sequence capable of forming a stem-loop. Formation of the stem-loop modifies (e.g., quenching) the fluorescence signals of the reporter sequence when the reporter sequence is hybridized to the oligonucleotide. This can be achieved, for example, by bringing one or more guanine based in the oligonucleotide into close proximity to the fluorophore(s) of the reporter sequence by virtue of the formation of the stem-loop. Disruption of the stem-loop, such as by hybridization of a target sequence to at least part of the hairpin-forming sequence, produces a detectable change in the fluorescence signals. | 2008-11-27 |
20080293581 | Rna Expression Microarrays - Provided are microarrays comprising spots comprising mixtures of cDNA molecules, the cDNA mixture being complementary and substantially quantitatively proportional to a mixture of mRNA molecules present in a cell or group of cells. Also provided are methods for determining expression of a gene in a cell or group of cells using the invention microarrays. Additionally provided are methods of determining the difference in expression of a first gene between a first cell or group of cells and a second cell or group of cells, using the invention microarrays. Also provided are microarrays comprising short RNAs, and methods of using these microarrays for detecting and quantifying microarrays in cells. | 2008-11-27 |
20080293582 | Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel - A method for prognostic or diagnostic assessment of a gastrointestinal-related disorder, such as ulcerative colitis, in a subject correlates the presence, absence, and/or magnitude of a gene in a sample with a reference standard to determine the presence and/or severity of the disorder, and/or the response to treatment for the disorder. The method enables identification of the effectiveness of candidate therapies. | 2008-11-27 |
20080293583 | Methods for diagnosing mood disorders - The present invention relates generally to the fields of neuroscience, proteomics and mood disorders. More particularly, the present invention relates to the identification of a group of proteins modulated in subjects with a mood disorder; methods for detecting or screening mRNA encoding these proteins and methods for diagnosing mood disorders. | 2008-11-27 |
20080293584 | Fluorescent silica nano-particle, fluorescent nano-material, and biochip and assay using the same - Colloidal silica particles containing a fluorescent dye compound, composed of a silica particle containing a silica component and a fluorescent dye compound chemically bound or adsorbed thereto, | 2008-11-27 |
20080293585 | 5'/3' Ratioing Procedure for Detection of Gene Rearrangements - The present invention relates to methods and kits useful for the detection of gene rearrangements and the diagnosis of a propensity to develop a disease condition caused by the gene rearrangements, wherein two PCR products are prepared from the 5′ side and from the 3′ side of a putative breakpoint of the gene of interest, and the ratio of the two products are measured. | 2008-11-27 |
20080293586 | FLUORESCENT PROBES FOR DNA DETECTION BY HYBRIDIZATION WITH IMPROVED SENSITIVITY AND LOW BACKGROUND - Minor groove binder-oligonucleotide probes are provided along with methods for their use wherein the probes have an attached fluorophore which, in an unhybridized form exhibits very low background signal. | 2008-11-27 |
20080293587 | Method of Screening a Biological Target for Weak Interactions Using Weak Affinity Chromatography - The present invention relates to a method of screening a biological target for transient weak interactions between the target and a library of ligands. The method includes the provision of a composition comprising a biological target and the provision of a plurality of stationary phases from such a composition. A plurality of ligand compositions is transported to the stationary phases to establish contacts between the ligands and the biological targets. Zonal retardation information are collected for each ligand, downstream of the stationary phases in order to select ligands with dissociation constants (Kd) in the range of 0.01 to 10 mM, exhibiting weak affinity to the target. | 2008-11-27 |
20080293588 | NANODISK CODES - The invention relates to nanodisk codes and methods of using the nanodisk codes in encoding and detection schemes. In one aspect, the invention relates to nanodisk codes having a binary encoding scheme and functionalized such that the encoding of the nanodisk codes is detectable. | 2008-11-27 |
20080293589 | Multiplex locus specific amplification - Methods are provided for amplifying a plurality of pre-selected target sequences from a complex background of nucleic acids. The targets are selected for amplification using splint oligonucleotides that are used to modify the ends of the fragments. The fragments have known end sequences and the splints are designed to be complementary to the ends. In one aspect the splint brings the ends of the fragment together and the ends are joined to form a circle. In another aspect the splint is used to add a common priming site to the ends of the target fragments. Specific loci are amplified and can be subsequently analyzed. | 2008-11-27 |
20080293590 | Multianalyte assay method - A plurality of groups of colorimetrically distinguishable metal nanoparticles are prepared to label specific analytes whose presence in a sample is under investigation, each group for specific analytes. After being mixed with the sample so that labeling can occur if the analyte or analytes are present, the sample is exposed to a sensor having probes for the analytes under investigation. Binding of any of the analytes present will carry the metal nanoparticle as well, which then enables colorimetric detection of each label to determine which if any of the analytes is present in the sample. In an alternative method the probes can be labeled with colorimetrically distinguishable metal nanoparticle labels and any binding events can be detected colorimetrically. | 2008-11-27 |
20080293591 | Repeatable Protein Arrays - The invention relates to a method of producing a protein array ( | 2008-11-27 |
20080293592 | Method For Covalently Immobilising Biomolecules on Organic Surfaces - The invention relates to a method for covalently immobilising probe-biomolecules on organic surfaces by means of photoreactive cross-linking agents which are used for covalently immobilising the probe-biomolecules on an organic surface. The inventive immobilising method consists in applying said probe-biomolecules and photoactive polymers and afterwards in cross-linking. | 2008-11-27 |
20080293593 | siRNA targeting casitas B cell lymphoma-B (CBL-B) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CBL-B. | 2008-11-27 |
20080293594 | SOLID PHASE FOR CAPTURE OF NUCLEIC ACIDS - A method of: providing a solid surface having a dendrimer molecule bound thereto and a single-stranded probe nucleic acid immobilized to the dendrimer; contacting the solid surface with a sample suspected or known to contain a double-stranded complimentary target nucleic acid; denaturing the target nucleic acids at thermal conditions and in a salt concentration sufficient to denature the target nucleic acids to produce denatured nucleic acids; and cooling the sample to allow hybridization of the denatured nucleic acids to the probe nucleic acids. An article having: one or more paramagnetic microbeads; a dendrimer molecule bound to the beads; and a probe nucleic acid immobilized to the dendrimer. | 2008-11-27 |
20080293595 | siRNA targeting protein tyrosine phosphatase-1B (PTP1B) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PTP1B. | 2008-11-27 |
20080293596 | Systems and Methods for the Generation of Crystalline Polymorphs - The present invention relates to systems and methods for generating polymorphs of compounds. In particular, the present invention provides high throughput systems and methods for generating and identifying new crystalline polymorphs that find use as improved drugs, pigments, explosives, nonlinear optical crystals, solid-state reactive compounds, and other polymorphic materials. | 2008-11-27 |
20080293597 | METHOD FOR INHIBITING HYDRATE FORMATION - A sterically hindered quaternary ammonium composition is prepared by contacting a solvent having hydroxyl functionality, a halohydrin, and a sterically hindered tertiary amine, under reaction conditions sufficient to produce a sterically hindered quaternary ammonium compound. The reaction proceeds with excellent yield. The resulting compounds are particularly useful for inhibiting formation of hydrates in hydrocarbon reservoirs and pipelines. Novel compositions of matter include sterically hindered quaternary ammonium compounds conforming to the formulas C | 2008-11-27 |
20080293598 | Rolling device and rolling device manufacturing method - A solid lubricating composition having resin material is disposed between an outer ring and an inner ring of a ball bearing. As the resin material contained in the solid lubricating composition, resin material having a property of being solidified when the resin material in a fluid state is irradiated with an ultraviolet beam is used. | 2008-11-27 |
20080293599 | METALWORKING LUBRICANT FORMULATIONS BASED ON SUPERCRITICAL CARBON DIOXIDE - A method for lubricating a metal workpiece during a metalworking process includes delivering supercritical carbon dioxide to the workpiece during the metalworking process. The supercritical carbon dioxide acts as a lubricant, coolant, chip evacuator, and/or carrier for another lubricant or corrosion inhibitor. | 2008-11-27 |
20080293600 | Multiple-Function Dispersant Graft Polymer - A grafted polymer, either polyolefin or polyester, containing monomers associated with sludge and varnish control as well as monomers associated with soot handling to provide a graft polymer exhibiting multiple performance attributes. Also described are methods for manufacturing these novel multiple-function graft polymers via solution and melt processes. Lubricating oil compositions containing these novel multiple-function polymers as an additive that display performance characteristics directed to good soot handling and sludge and varnish control as well as control of viscosity increase are described. | 2008-11-27 |
20080293601 | Method for Preparing an Imidized Polymer - The invention relates to a process for preparing an imidized polymer in a mixing or kneading device, by a reaction of a mixture, comprising a polymer, containing anhydride groups or derivatives thereof and an aromatic polyamine compound, wherein the reaction is carried out in the presence of an acid. With this process an imidized polymer can be obtained with a reduced amount of incomplete reacted anhydride groups with respect to the anhydride groups originally present in the polymer as well as a low amount of free and amid-bound aromatic polyamine. The invention further relates to a solid compound, and in particular a solid multifunctional viscosity modifier comprising a polymer comprising between 0.1 and 10 functional groups per 1000 C-atoms, the functional groups comprising aromatic amine based imide groups, wherein the ratio of imide groups with respect to the functional groups is more than 0.85, preferably more than 0.90 and most preferably more than 0.95 and to a lubricating oil, comprising the multifunctional viscosity modifier according to the invention, wherein the amount of low molecular weight aromatic polyamine in the oil is smaller than 10 ppm. | 2008-11-27 |
20080293602 | GLYCEROL DERIVATIVES AND METHODS OF MAKING SAME - Symmetrical polyols, polyol esters, polyesters, polyurethanes, triazoles, and polyvinylethers derived from glycerol and methods of making the symmetrical polyols, polyesters, polyurethanes, polyhydroxyvinylethers and triazoles are discussed. Also provided is a method of making serinol. | 2008-11-27 |
20080293603 | Oil-Cleansing Composition - The objective of this invention is to provide an oil-based cleansing composition which retains high performance capability for cleansing, is free from the occurrence of cloudiness in the appearance and does not cause the reduction of the performance capability for massaging, even when water is interfused therein, and further is reduced in the irritation to an eye and is of good safety. | 2008-11-27 |
20080293604 | Dosage Element - Laundry or dishwasher detergent elements ( | 2008-11-27 |
20080293605 | Composition and Method - A low-foaming composition for cleaning a ware-washing machine comprises water, an alkoxylate, an acid (preferably citric acid), and preferably a phase separation promoter (for example a polyethylene glycol or an ionic salt). The composition is in two separate layers under ambient conditions. | 2008-11-27 |
20080293606 | Organosilicon Compound-Containing Compositions - Defoamer compositions contain a carrier oil and at least one particulate filler of less than 40°, measured with water as a surrounding phase. The defoamers are surprisingly more active than prior art defoamers. | 2008-11-27 |
20080293607 | Alkaliphilic Bacillus Species alpha-Amylase Variants, Compositions Comprising alpha-Amylase Variants, And Methods of Use - Disclosed are variants of the α-amylase derived from | 2008-11-27 |
20080293608 | Composition and Method - A filter cleaning composition for use between dishwashing operations in a dishwasher, the composition comprising at least one non-starch carbohydrase, for example a cellulase. A method of using said composition is also disclosed. | 2008-11-27 |
20080293609 | ABSORPTIVE PARTICLES - A method to obtain particles which can absorb large quantities of perfume. The resulting particles are mechanically stable, flow freely, and have no tendency to stick together even when being charged with a great quantity of perfume. The perfume can be stabilized in the particles in such a way that the contained fragrances essentially do not decompose. Also disclosed are the aftertreatment of such particles as well as a detergent composition containing the inventive particles. | 2008-11-27 |
20080293610 | Use and production of storage-stable neutral metalloprotease - The present invention provides methods and compositions comprising at least one neutral metalloprotease enzyme that has improved storage stability. In some embodiments, the neutral metalloprotease finds use in cleaning and other applications. In some particularly preferred embodiments, the present invention provides methods and compositions comprising neutral metalloprotease(s) obtained from | 2008-11-27 |
20080293611 | POLYOL OXIDASES - The present invention provides compositions and methods for producing a polyol oxidase in micoroorganisms, and the use of polyol oxidases in cleaning compositions. The invention includes cleaning compositions that contain combinations of two or more POx oxidases, and cleaning compositions that contain combinations of two or more POx oxidases and a perhydrolase. In particular, the invention provides methods for expressing polyol oxidases in bacterial hosts for use in detergent applications for cleaning, bleaching and disinfecting. | 2008-11-27 |
20080293612 | Surfactant Systems for Surface Cleaning - The present invention relates to aqueous surfactant systems that in diluted or undiluted form may be used for cleaning surfaces or may be used as an active cleaning base in various ready-to-use (or in-use) aqueous cleaning compositions suitable for surface cleaning. The invention also relates to a cleaning system comprising a surfactant system of the invention. According to the invention the cleaning efficacy of the surfactant system or cleaning system is increased by reducing or minimizing the size of the surfactants typically used in surfactant systems and reducing or minimizing the water solubility of the surfactant system. | 2008-11-27 |
20080293613 | Premoistened cleaning disposable substrate and method of incorporation of a cleaning composition into said substrate - The present invention is based in part on the discovery that impregnating a cleaning substrate with a nonionic, linear polymer unexpectedly improves the cleaning efficacy of the article and prevents redeposition of soil and dirt onto the cleaned hard or soft surface. The nonionic, linear polymer is, for example, polyacrylamide. In addition, a method of incorporation of a cleaning composition into said substrate is disclosed. | 2008-11-27 |
20080293614 | ZEOLITE COMPOSITE MATERIALS FOR WASTE ODOR CONTROL - A composite material for environmental odor control is useful in controlling odors from waste, for example, as an alternative daily cover for landfills and in composting applications. The composite material includes a fiber web and a zeolite containing metals to promote absorption of odorous gas. | 2008-11-27 |
20080293615 | Dimensionally Stable Solid Rinse Aid - The present invention is a solid rinse aid composition and methods of making and using the same. The solid rinse aid composition generally includes sodium sulfate and urea as solidification agents and an effective amount of an alcohol ethoxylate compound sheeting agent component and an effective amount of defoamer component. The solid rinse aid composition may also incorporate a preservative system including sodium bisulfate. The solid rinse aid composition may be phosphate-free, aminocarboxylate-free, and GRAS if desired. | 2008-11-27 |
20080293616 | Use of 2-(1,1,4-Trimethylpent-3-Enyl)-4,7-Dihydro-1,3-Dioxepine - The use of 2-(1,1,4-trimethylpent-3-enyl)-4,7-dihydro-1,3-dioxepin as an agent for providing (a) hair or (b) textile fibres with a fresh smell is described. | 2008-11-27 |
20080293617 | Implantable Putty Material - The present invention provides compositions for an implantable putty material for delivery of active compounds to a patient. More specifically, the present invention provides a material having a pH of between about 3 and 6 and possessing putty-like physical properties, wherein the composition of the material includes collagen and water. The present invention also provides a method for using the implantable putty material. | 2008-11-27 |
20080293618 | CYCLOPROPYL-FUSED PYRROLIDINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS - The present invention relates to DP IV-inhibitors of formula (1) | 2008-11-27 |
20080293619 | COMPOSITIONS AND METHODS FOR TREATING MALARIA WITH CUPREDOXIN AND CYTOCHROME - The present invention relates to cupredoxin and cytochrome and their use, separately or together, to inhibit the spread of parasitemia in mammalian red blood cells and other tissues infected by the malaria parasite, and in particular the parasitemia of human red blood cells by | 2008-11-27 |
20080293620 | Immunogenic Glycopeptides for Diagnosing Pathogenic Microorganisms Infections - A method for diagnosing an infection in a patient likely to be infected with a pathogenic microorganism, comprising the detection of CD4+ T lymphocytes recognizing at least one glycopeptide derived from said pathogenic microorganism, essentially consisting of a glycosylated T epitope, comprising from 14 to 25 amino acids, among which at least one neutral amino acid is bonded to a disaccharide or to a trisaccharide, and at least 15% of said amino acids are prolines, one of the prolines being located in position −1 to −4, relative to the position of said neutral amino acid. | 2008-11-27 |
20080293621 | Methods for Prolonging Feline Life - Methods for prolonging feline life by maintaining a feline on a food having reduced levels of protein, phosphorus, and sodium when compared to a standard feline maintenance food. | 2008-11-27 |
20080293622 | METHODS OF INDUCING OVULATION - The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms. | 2008-11-27 |
20080293623 | ENRICHED HAPTOGLOBIN POLYMERS FOR THE TREATMENT OF DISEASE - Haptoglobin (Hp) removes cell-free Hemoglobin (Hb), with different physiological effects depending on the particular Hp polymer. We propose that material enriched for alpha 1 chain Hp polymeric forms, such as those made from Cohn fraction V precipitate, will be more suitable for the treatment of certain diseases benefiting from both an antioxidant and anti-inflammatory component, such as for hemolytic disease. Material enriched for alpha-2 chain Hp polymeric forms, made for example from Cohn fraction IV precipitate, will be more suitable for treatment of diseases where an angiogenic, and/or inflammatory affect, and/or limited extravasation is desirable. | 2008-11-27 |
20080293624 | Stabilized FGF formulations containing reducing agents - Stabilized FGF compositions are provided. The compositions comprise FGF or variant thereof and at least one reducing agent in an amount sufficient to inhibit FGF oxidation. Methods for increasing stability of FGF or variant thereof in a liquid or lyophilized composition and for increasing storage stability of such a composition are also provided. | 2008-11-27 |
20080293625 | Diagnosis of Inflammatory Bowel Diseases, More Particularly Ulcerative Colitis - The present invention concerns goblet cell antigen, a method for detecting antibodies directed against goblet cell antigen, a method based thereon for diagnosis of inflammatory bowel diseases and a kit for diagnosis of inflammatory bowel diseases, as well as monoclonal antibodies directed against goblet cell antigen. | 2008-11-27 |
20080293626 | Pigment epithelium-derived factor as a therapeutic agent for vascular leakage - The present invention relates to method of treating a patient with a condition involving increased vascular permeability or increased angiogenesis comprising administering to the patient a therapeutically effective amount of PEDF, PEDF 44 AA peptide, a homolog of the PEDF 44 AA peptide, a homolog of the PEDF 44 AA peptide wherein amino acid residues glutamate the (101) amino acid position, isoleucine at the (103) amino acid position, leucine at the (112) and serine at the (115) amino acid position are unchanged, or an agent that activates the PEDF receptor. Conditions for treatment include, but are not limited to, sepsis acute respiratory distress syndrome, nephrotic syndrome, diabetic neuropathy, preproliferative diabetic retinopathy, cancer or proliferative diabetic retinopathy. | 2008-11-27 |
20080293627 | Thyrotropin Receptor Preparations, Binding Regions Thereof, Antibody and Hormone Interactions Therewith, and Uses Thereof - A mutated TSHR preparation which includes at least one point mutation characterised in that at least amino acid Arg at a position corresponding to amino acid 255 of a full length human TSHR has been mutated to a different amino acid residue in said mutated TSHR preparation, whereby said mutated TSHR preparation differentially interacts with patient serum stimulating TSHR autoantibodies, patient serum blocking TSHR autoantibodies and TSH, in that (i) the stimulatory effect of patient serum stimulating TSHR autoantibodies interacting with the mutated TSHR preparation is substantially reduced or essentially abolished, when compared to the stimulatory effect of the patient serum stimulating TSHR autoantibodies interacting with a reference TSHR preparation which has an amino acid sequence corresponding to that of said mutated TSHR preparation with the exception that said mutation of Arg at a position corresponding to amino acid 255 of a full length human TSHR is not present in said reference TSHR preparation, (ii) the stimulatory effect of TSH when interacting with the mutated TSHR preparation is essentially unaffected, when compared to the stimulatory effect of TSH interacting with said reference TSHR preparation, and (iii) the blocking effect of patient serum blocking TSHR autoantibodies interacting with the mutated TSHR preparation is essentially unaffected or increased, when compared to the blocking effect of the patient serum blocking TSHR autoantibodies interacting with said reference TSHR preparation, whereby said mutated TSHR preparation is effective in the differential screening and identification of patient serum stimulating TSHR autoantibodies, patient serum blocking TSHR autoantibodies and TSH in a sample of body fluid being screened. | 2008-11-27 |
20080293628 | Methods and Compositions for the Inhibition of Thrombus Formation - The present invention is directed to anti-platelet peptides that may be used in various methods for the treatment or prophylaxis of thrombosis. More specifically, the specification describes methods and compositions for making and using compositions GPIbα fragments as anti-platelet agents. The present invention is also directed to peptides that inhibit intracellular function of 14-3-3. | 2008-11-27 |
20080293629 | Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention. | 2008-11-27 |
20080293630 | Mucoadhesive Pharmaceutical Compositions Comprising Chemoattractants - The invention relates to a mucoadhesive pharmaceutical composition comprising a polymer and a chemoattractant wherein the pH of the composition is greater than 6 which is useful in the treatment of a anogenital or oral disease, particularly an anogenital or oral disease cause by the human papillomavirus. | 2008-11-27 |
20080293631 | Treatment for Autoimmune and Inflammatory Conditions - The present invention provides methods for preventing the elevation of blood glucose levels, for preventing or delaying the onset of autoimmune and inflammatory diseases or glucose-associated conditions, and for preventing or reducing inflammation in individuals suffering from an autoimmune or inflammatory diseases, the methods comprising administering to subjects in need thereof an effective amount of activated Protein C or precursor Protein C. | 2008-11-27 |
20080293632 | Use of natriuretic peptides for the treatment of stature disorders related to shox gene - The invention relates to the use of natriuretic peptides (ANP or BNP) for the preparation of pharmaceutical compositions for the treatment of short stature in a subject being suspected of having a genetic defect in the human SHOX gene. Further, the invention relates to use of natriuretic peptides in combination with a growth protein and/or a SHOX protein for the preparation of pharmaceutical compositions for the treatment of patients having a SHOX gene disorder. The invention also relates to the use of natriuretic peptides (ANP and BNP) in combination with a SHOX protein for the preparation of pharmaceutical compositions for the treatment of patients with cardiovascular diseases. The invention also comprises an article of manufacture comprising packaging material and a pharmaceutical composition comprising natriuretic peptides. | 2008-11-27 |
20080293633 | Pharmaceutical Formulations, Methods, and Dosing Regimens for the Treatment and Prevention of Acute Coronary Syndromes - The invention provides methods and formulations for treating and preventing acute coronary syndromes. The methods of the instant invention provide safe and effective doses of an Apolipoprotein A-I Milano: phospholipid complex to reduce and stabilize atherosclerotic plaque. Pharmaceutical formulations of the Apo A-I Milano:phospholipid complexes are also provided. | 2008-11-27 |
20080293634 | C-MET RECEPTOR REGULATION BY ANGIOTENSIN IV (AT4) RECEPTOR LIGANDS - The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis, cancer metastasis, adipogenesis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, including cancer, obesity and conditions associated with obesity, and other disorders, for example, by altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor. | 2008-11-27 |
20080293635 | Angiogenic composition - The present invention relates to a amphiphilic polymer in the preparation of a therapeutic composition for promoting angiogenesis at its site of administration, comprising a complex between a polymer and a PDGF, wherein the polymer is amphiphilic. | 2008-11-27 |
20080293636 | Protein Constructs Designed for Targeting and Lysis of Cells - The invention relates to a protein construct, comprising (i) a targeting moiety that is capable of binding to a target cell, and (ii) an effector immunogenic moiety that is capable of triggering an existing, vaccine-induced or natural, immune response. The protein construct, that is preferably in the form of a heteromultimeric protein, is useful for redirecting an immune response that was pre-existing in a patient, toward an undesired target cell. | 2008-11-27 |
20080293637 | Cross-linked collagen and uses thereof - The present invention discloses collagen cross-linked in a micro to non-fibrillar form and at a high concentration. The cross-linked collagen gel has improved volume stability or persistence than collagen cross-linked at a neutral pH. Also disclosed are methods for preparing the inventive cross-linked collagen and using such for augmenting soft tissues in mammals. | 2008-11-27 |
20080293638 | ALBUMIN-FUSED CILIARY NEUROTROPHIC FACTOR - The invention relates to a fusion protein comprising an albumin, or a fragment or a variant or a derivative thereof and at least one biologically active peptide which activates the ciliary neurotrophic factor (CNTF) receptor, or a fragment or variant or a derivative thereof. | 2008-11-27 |
20080293639 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES CHARACTERIZED BY AN INFLAMMATORY RESPONSE - This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route. | 2008-11-27 |
20080293640 | Polypeptide inhibitors of HSP27 kinase and uses therefor - The present invention provides polypeptide inhibitors of HSP27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses. | 2008-11-27 |
20080293641 | BIOLOGICALLY ACTIVE PEPTIDES - Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced therefrom are also disclosed. | 2008-11-27 |
20080293642 | C-Glycosylisoflavones Having Alkylaminoalkoxyl Substituent, Preparation and Use of the Same - The present invention relates to C-Glycosylisoflavones having alkylaminoalkoxyl substituent and pharmaceutically acceptable salts thereof, a process for the preparation thereof, pharmaceutical compositions comprising an effective amount of a compound of the formula (I), and to the use of these compounds or compositions for the treatment or prevention of cardio- and cerebrovascular diseases, in particular for the treatment of various cardiocerebral hypoxic-ischemic diseases, for the treatment or prevention of diabetes mellitus and complications thereof, and for the treatment or prevention of chemical poisoning, in particular alcoholism. | 2008-11-27 |
20080293643 | Crystalline Form I of 3,4'5-Trihydroxy-Stilbene-3-B-D Glucoside - The present invention relates to a novel crystalline form of a Compound 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside (polydatin) and a method of preparation and use thereof, and to a pharmaceutical composition containing crystalline form I of 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside. Crystalline form I of 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside of the present invention has a stable crystalline morphology, a definite melting point and a good chemical stability. Such a novel form of 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside possesses the properties required for the preparation of solid formulations and is easily tabletable and readily formable when formulated, which allows for substantial decrease in raw materials costs, more facile operations in production and easier control over quality in industrial drug production, and moreover, better convenience in storage. | 2008-11-27 |
20080293644 | GUAVA EXTRACT - The invention describes the preparation, isolation and use of an extract of guava fruit for the treatment of a disease or condition related with, caused by or mediated by dipeptidyl peptidase IV. | 2008-11-27 |
20080293645 | Antiparasitic combination and method for treating domestic animals - This invention relates an antiparasitic combination for conveniently treating multiple types of parasites in domestic animals. Specifically, this invention provides a convenient combination and a method for removing worms from a gastrointestinal tract of a domestic animal while also preventing heartworm. The antiparasitic combination for the treatment of domestic animals may include an effective amount of praziquantel, an effective amount of pyrantel pamoate, an effective amount of febantel, and an effective amount of ivermectin. Typical worms removed may include tapeworms, hookworms, whipworms and ascarids. | 2008-11-27 |
20080293646 | MACROLIDES - The invention relates to compounds of Formula (I): | 2008-11-27 |
20080293647 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer - There is provided according to the invention a method of treating a patient with bladder cancer by administering a effective amount of a vitamin D compound in combination with one or more other antiproliferative agents. Also provided are uses of a vitamin D compound in combination with one or more other antiproliferative agents and compositions for use in the method. | 2008-11-27 |
20080293648 | Compositions and Methods for Cancer Treatment - This invention provides methods, novel formulations and kits to reduce the toxicity of anticancer drugs. Disclosed are therapeutics and treatment methods employing anticancer drags that exhibit a known toxicity, including, for example, adriamycin, campthothecin, and the like, chemically linked to a phosphonoformic acid partial ester resulting in a novel formulation that significantly decreases drug-related toxicity, enhances synergy with other chemotherapeutic drugs and provides increased efficacy against drug-resistant cancers. | 2008-11-27 |
20080293649 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS - The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection. | 2008-11-27 |
20080293650 | Fused Heterocyclic Compounds and Use Thereof - Fused heterocylic compounds of the following Formula | 2008-11-27 |
20080293651 | CYTOSINE NUCLEOSIDE ANALOGS AND ISOFLAVONES AND USES THEREOF - Methods, uses, compositions and kits relating to the inhibition and/or prevention of undesirable cell proliferation, and prevention and/or treatment of diseases or disorders associated with such proliferation, such as cancer, using a cytosine nucleoside analog and an isoflavone, are described. | 2008-11-27 |
20080293652 | Combination of Ad-P53 and Chemotherapy for the Treatment of Tumours - The present invention relates to the use of p53 gene therapy to treat recurrent cancers in combination with a radio- or chemotherapy. Patients with recurring cancers are treated with a p53 expression construct followed by subsequent radio- or chemotherapy treatment. Viral and non-viral delivery systems, as well as various radio- and chemotherapy regimens are disclosed. | 2008-11-27 |
20080293653 | Method of treating autoimmune diseases - The invention features a method of inducing an apoptosis-resistant cell to undergo apoptosis, in which the cell is associated with an autoimmune disease such as multiple sclerosis. The method involves sensitizing the cell to apoptosis stimuli by treating the cell with an IAP antisense oligonucleotide, so that the cell undergoes apoptosis at a site of autoimmune disease. | 2008-11-27 |
20080293654 | Therapeutic methods using Smads - Methods of inducing the expression of a Smad in a cell or tissue comprising the step of contacting the cell or tissue capable of expressing the Smad with a bone morphogenic protein are provided. Methods of inducing tissue formation and repairing a tissue defect or regenerating tissue, at a target locus in a mammal comprising the step of administering to the target locus a Smad are also provided. | 2008-11-27 |
20080293655 | Novel tandem siRNAS - The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of two or more target genes. | 2008-11-27 |
20080293656 | PROCESSING NUCLEIC ACID - The present invention relates to a method of processing nucleic acid. More particularly, it relates to a method of purifying extra-chromosomal DNA by removing cell debris and/or RNA from a process stream comprising extra chromosomal DNA and a precipitate resulting from preceding cell lysis and/or precipitation reactions. It also relates to nucleic acid, particularly extra chromosomal DNA, purified by a method of the invention; a pharmaceutical composition comprising or consisting of the same and apparatus for said method. | 2008-11-27 |
20080293657 | MODULATION OF THE EXPRESSION OF STAT-1-DEPENDENT GENES - The present invention relates to decoy-oligonucleotides and antisense-oligonucleotides having the nucleic acid sequence according to SEQ ID NO: 1 to 43 as well as the use thereof as medicaments. | 2008-11-27 |
20080293658 | ANTISENSE OLIGONUCLEOTIDES CAPABLE OF INHIBITING THE FORMATION OF CAPILLARY TUBES BY ENDOTHELIAL CELLS - A pharmaceutical composition that blocks angiogenesis comprising as active agent at least one substance selected from the group consisting of (i) a nucleic acid molecule of a gene coding for protein IRS-1, a complementary sequence or a fragment thereof and (ii) a molecule which inhibits expression of a nucleic acid molecule according to (i). | 2008-11-27 |
20080293659 | FC gamma RIIA-specific nucleic acid interference - The present invention provides methods and compositions for attenuating expression of FcγRIIA. In general, the described methodology involves the use of RNAi constructs that are targeted to a FcγRIIA mRNA sequence. | 2008-11-27 |
20080293660 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF - Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies. | 2008-11-27 |
20080293661 | METHOD FOR TREATING CHRONIC LYMPHOID LEUKEMIA - Embodiments of the invention relates to the treatment of chronic lymphoid leukemia. The invention provides treatment, diagnostic, and drug discovery strategies for chronic lymphoid leukemia. Reconstitution of RhoH expression in vitro inhibits neoplastic proliferation and the process of trans-endothelial migration that underlies much of the pathology of CCL. RhoH reconstitution also limits malignant progression in vivo. Therefore, RhoH reconstitution represents a new therapeutic strategy in the fight against chronic lymphoid leukemia. | 2008-11-27 |
20080293662 | RNAi MODULATION OF THE BCR-ABL FUSION GENE AND USES THEREOF - The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides. | 2008-11-27 |
20080293663 | CELLULAR GENES REGULATED BY HIV-1 INFECTION AND METHODS OF USE THEREOF - This invention provides cellular gene products which have anti-apoptotic activity in HIV-1 infected cells and provides agents for the inhibition of the cellular gene products. | 2008-11-27 |
20080293664 | Non-nucleoside reverse transcriptase inhibitors - Compounds of formula I, wherein R | 2008-11-27 |
20080293665 | Purine Nucleotide Derivatives - This invention provides novel 8-carbyl substituted Camps (adenosine 3′,5′-cyclic monophosphorothioate) and a novel procedures for the preparation of 8-Br-cAMP, a key starting material. | 2008-11-27 |
20080293666 | Antibacterial Agents - The invention provides compounds of formula (I) and salts thereof: R | 2008-11-27 |
20080293667 | Lipid analogs for combating tumors - The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the activity of the viral infection. | 2008-11-27 |
20080293668 | [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides - A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2′,3′-dideoxy-2′,3′-didehydro-pyrimidine nucleoside or a [5-carboxamido or 5-fluoro]-3′-modified-pyrimidine nucleoside, or a mixture or a pharmaceutically acceptable derivative thereof, including a 5′ or N | 2008-11-27 |
20080293669 | Composition Containing Beta-Glucan, Method of Producing the Same and Foods, Drinks or Skin Moisturizers Containing the Composition - It is intended to utilize β-glucan produced by a bacterium belonging to | 2008-11-27 |
20080293670 | Edible tremella polysaccharide for prevention and/or improvement of intestinal disorder - It has been found that the polysaccharide isolated from a hot water extract of a Tremella mushroom without adding a chemical reagent has a novel effect of preventing and/or treating of intestinal disorder. The Tremella polysaccharide has excellent stability, water absorbing and holding ability, and swelling capacity, so it can be used to raise fecal water content and increase fecal volume, so as to improve intestinal disorder characterized by constipation and symptom caused by constipation. | 2008-11-27 |
20080293671 | Combination of Polychitosamine and Fibrate for the Prevention and Treatment of Hyperlipidemia - The present invention relates to pharmaceutical compositions comprising a fibrate (e.g. ciprofibrate, gemfibrozil, benzafibrate, and fenofibrate) and a polychitosamine (e.g. chitosan) having molecular weights of less than 650 Kda and degrees of deacetylation of from 70% to 100%. Uses of said compositions for the treatment of hyperlipidemia and associated conditions (e.g. hypercholesterolemia, atherosclerosis, coronary heart disease and cardiovascular disease) or as functional foods are also disclosed. | 2008-11-27 |
20080293672 | Lipid conjugates in the treatment of disease - The invention relates to methods of use for compounds in treating, reducing the incidence, reducing the severity or pathogenesis of an intestinal disease or condition in a subject, including, inter alia, inflammatory bowel disease, Crohn's disease, ulcerative colitis, or a combination thereof. | 2008-11-27 |
20080293673 | N-ACETYGLUCOSAMINE DERIVATIVES AND USE THEREOF - The present invention relates to An N-acetylglucosamine derivative represented by the following formula (1), and a hyaluronic acid production promoting agent containing the same and a skin external preparation containing the same: | 2008-11-27 |
20080293674 | Azinyl Imidazoazine and Azinyl Carboxamide - The invention relates to azinylimidazoazines of structure (I) and their salts and N-oxides, | 2008-11-27 |
20080293675 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE - The structure and preparation of antibiotics incorporating borinic acid complexes are disclosed, especially hydroxyquinoline, imidazole and picolinic acid derivatives, along with compositions of these antibiotics and methods of using the antibiotics and compositions as bactericidal and fungicidal agents as well as therapeutic agents for the treatment of diseases caused by bacteria and fungi. | 2008-11-27 |
20080293676 | Insecticidal Agents Based on Selected Insecticides and Safeners - Insecticidal compositions characterized by an effective amount of an active ingredient combination comprising
| 2008-11-27 |
20080293677 | Use of Alternating Amine and Non-Amine Bisphosphonate Combinations For Treating Osteoporosis - A method of treating osteoporosis in a human in need thereof by administering alternating amine and non-amine bisphosphonates in a defined dosing schedule. The invention demonstrates an effective response and sustained benefit in the treatment of osteoporosis. Particularly, the method involves administration of a time-dependent dose of more than one bisphosphonate, specifically, alternating administration of a first bisphosphonate with a second bisphosphonate, wherein at least one bisphosphonate is administered in a stepped-up dosage amount. | 2008-11-27 |
20080293678 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use - The invention describes compositions and kits comprising at least qrie organic nitric oxide enhancing salt of an angiotensin converting enzyme inhibitor, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; Q) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The organic nitric oxide enhancing compounds that form salts with the angiotensin converting enzyme inhibitors are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. | 2008-11-27 |